Jackson T. WrightJr

Jackson T. WrightJr

Auto-generated profile, based on publicly available information

Jackson T. WrightJr

University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH (J.T.W.).

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2005 in JAMA
Verified
Journal Article
Open access
PDF file
JWJackson T. Wright
Jackson T. Wright
JDJ. Kay Dunn
J. Kay Dunn
JCJeffrey A. Cutler
Jeffrey A. Cutler
BDBarry R. Davis
Barry R. Davis
WCWilliam C. Cushman
William C. Cushman
GHGabriel B. Habib
Gabriel B. Habib
Cardiovascular disease (CVD) has become the leading cause of morbidity and mortality worldwide, and elevated blood pressure (BP) is a leading contributor to this phenomenon.1,2 The population of blacks with hypertension has the highest morbidity and mortality from hypertension of any population group in the United States and is among the highest in the world.3,4 Mortality related to hypertension and the risk of end-stage renal disease (ESRD), coronary heart disease (CHD), heart failure (HF), and stroke are increased in the black compared with the white population in the United States.4,5 While the benefits of lowering elevated BP in reducing cardiovascular morbidity and mortality are well established, until recently well-controlled studies comparing different classes of antihypertensive agents for reducing cardiovascular complications of hypertension were not available.

1 April 2014 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
JWJackson T. Wright
Jackson T. Wright
LFLawrence J. Fine
Lawrence J. Fine
DLDaniel T. Lackland
Daniel T. Lackland
GOGbenga Ogedegbe
Gbenga Ogedegbe
CHCheryl Himmelfarb
Cheryl Himmelfarb

1 January 2017 in Hypertension
Verified
Journal Article
Closed access
PDF file
PDPaul E Drawz
Paul E Drawz
NPNicholas M Pajewski
Nicholas M Pajewski
JBJeffrey T Bates
Jeffrey T Bates
NBNatalie A Bello
Natalie A Bello
WCWilliam C Cushman
William C Cushman
MRMahboob Rahman
Mahboob Rahman
The effect of clinic-based intensive hypertension treatment on ambulatory blood pressure (BP) is unknown. The goal of the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory BP ancillary study was to evaluate the effect of intensive versus standard clinic-based BP targets on ambulatory BP. Ambulatory BP was obtained within 3 weeks of the 27-month study visit in 897 SPRINT participants. Intensive treatment resulted in lower clinic systolic BP (mean difference between groups=16.0 mm Hg; 95% confidence interval, 14.1–17.8 mm Hg), nighttime systolic BP (mean difference=9.6 mm Hg; 95% confidence interval, 7.7–11.5 mm Hg), daytime systolic BP (mean difference=12.3 mm Hg; 95% confidence interval, 10.6–13.9 mm Hg), and 24-hour systolic BP (mean difference=11.2 mm Hg; 95% confidence interval, 9.7–12.8 mm Hg). The night/day systolic BP ratio was similar between the intensive (0.92±0.09) and standard-treatment groups (0.91±0.09). There was considerable lack of agreement within participants between clinic systolic BP and daytime ambulatory systolic BP with wide limits of agreement on Bland–Altman plots. In conclusion, targeting a systolic BP of <120 mm Hg, when compared with <140 mm Hg, resulted in lower nighttime, daytime, and 24-hour systolic BP, but did not change the night/day systolic BP ratio. Ambulatory BP monitoring may be required to assess the effect of targeted hypertension therapy on out of office BP. Further studies are needed to assess whether targeting hypertension therapy based on ambulatory BP improves clinical outcomes. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01835249.

10 September 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
SJStephen P. Juraschek
Stephen P. Juraschek
JHJiun-Ruey Hu
Jiun-Ruey Hu
JCJennifer L. Cluett
Jennifer L. Cluett
AIAnthony Ishak
Anthony Ishak
CMCarol Mita
Carol Mita
KMKenneth J. Mukamal
Kenneth J. Mukamal
Whether intensive blood pressure–lowering treatment in adults with hypertension causes orthostatic hypotension is unclear. This systematic review and individual participant-based meta-analysis exam... Background: Although intensive blood pressure (BP)–lowering treatment reduces risk for cardiovascular disease, there are concerns that it might cause orthostatic hypotension (OH). Purpose: To exami...

10 November 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
JWJackson T. Wright
Jackson T. Wright
PWPaul K Whelton
Paul K Whelton
KJKaren C. Johnson
Karen C. Johnson
JSJoni K. Snyder
Joni K. Snyder
DRDavid M. Reboussin
David M. Reboussin
FGfor the SPRINT Research Group
for the SPRINT Research Group
The SPRINT (Systolic Blood Pressure Intervention Trial) results have influenced clinical practice but have also generated discussion regarding the validity, generalizability, and importance of the findings. Following the SPRINT primary results manuscript in 2015, additional results and analyses of the data have addressed these concerns. The primary objective of this article is to respond to key questions that have been raised.

1 September 2022 in Hypertension
Verified
Journal Article
Closed access
PDF file
WCWilliam C. Cushman
William C. Cushman
RRRobert J. Ringer
Robert J. Ringer
CRCarlos Jose Rodriguez
Carlos Jose Rodriguez
GEGregory W. Evans
Gregory W. Evans
JBJeffrey T. Bates
Jeffrey T. Bates
FGfor the SPRINT Research Group
for the SPRINT Research Group
Background: The SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated reductions in major cardiovascular disease events and mortality with an intensive systolic blood pressure (SBP) goal intervention. However, a detailed description of the blood pressure intervention, antihypertensive medication usage, blood pressure levels, and rates and predictors of blood pressure control has not been reported previously. Methods: Hypertensive participants (n=9361) 50 years and older with elevated cardiovascular disease risk were randomized 1:1 to SBP goal <120 mm Hg or SBP goal <140 mm Hg. Guideline-recommended antihypertensive medications and dosing were provided at no cost. Intensive group participants were started on at least 2 medications, and medications were adjusted monthly until SBP goal was achieved, if feasible. Standard group participants were treated to achieve SBP 135 to 139 mm Hg. Results: Baseline blood pressure (median±interquartile range) was 138±19/78±16 mm Hg. For intensive group participants, percent at goal rose from 8.9% at baseline to 52.4% at 6 months and average antihypertensive medications rose from 2.2 to 2.7; SBP was <120 mm Hg in 61.6% and <130 mm Hg in 80.0% at their final visit. For the standard group participants, percent at goal rose from 53.0% at baseline to 68.6% at 6 months, while antihypertensive medications fell from 1.9 to 1.8. From 6 to 36 months, median SBP was stable at 119±14 mm Hg for intensive and 136±15 mm Hg for standard participants, with stable numbers of medications. Few predictors of SBP control were found in multiple regression models. Conclusions: These results may inform and help replicate the benefits of SPRINT in clinical practice. Registration: URL: http://www.clinicaltrials.gov ; Unique identifier: NCT01206062.